Skip to main content

10 Best Vaccine Stocks to Buy Now

10 Best Vaccine Stocks to Buy Now

covid vaccine stocks

BioNTech’s drug pipeline also includes multiple early-stage candidates targeting various types of cancer. The uptick in coronavirus cases could push more people to get vaccinated — and that may encourage healthcare providers to increase vaccine orders. I wouldn’t expect this to result in a major surge in sales for Pfizer or Moderna right away. But it could show us that coronavirus vaccines aren’t just pandemic products and may continue to grow earnings for vaccine makers over time. While Novavax entered the Covid vaccine race in the Spring, along with Moderna and Pfizer/BioNtech who have now started rolling out their vaccines, the company has faced delays in its timeline. The first readouts from its phase 3 trials are expected around Q – likely one quarter behind the front runners.

COVID Is Making a Comeback: Should You Buy These 2 Stocks? – The Motley Fool

COVID Is Making a Comeback: Should You Buy These 2 Stocks?.

Posted: Sun, 27 Aug 2023 07:00:00 GMT [source]

Novavax (NVAX -6.95%) deserves inclusion as a top COVID vaccine stock even though it hasn’t won EUA or approval anywhere yet. « We recognize that for some, the FDA approval of a vaccine may now instill additional confidence to get vaccinated, » acting FDA Commissioner Janet Woodcock said in a statement. « Today’s milestone puts us one step closer to altering the course of this pandemic in the US. » Pfizer and BioNTech are seeking U.S. approval for use of their shots on children ages 5-11, while Moderna is testing its shot in kids as well. So far, there is no evidence that BA.2.86 spreads faster or causes more serious infections than previous versions.

Firstly, global Covid-19 cases have been trending significantly higher with daily new cases standing at over 800k over the last week, driven partly by infections in India and South America. Although about 38% of U.S. adults have now received at least one dose of Covid-19 shots, per the Bloomberg Vaccine Tracker, the global rollout of vaccines has been much slower, with under 8% of the global population vaccinated. Moderna’s share price has almost tripled in 2021 after surging 434% last year. The stock’s inclusion in the S&P 500 in July further propelled it to a record and sent it soaring past analysts’ price targets. The company is selling its COVID-19 vaccine at cost during the pandemic, meaning that it doesn’t affect the company’s profitability for now. Far fewer doses of J&J’s vaccine have been administered so far compared to the Pfizer-BioNTech and Moderna vaccines.

Top COVID Vaccine Stocks That Wall Street Is Bullish About

The companies are all planning to launch vaccines in September that block the XBB.1.5 subvariant of omicron. Today, it accounts for just north of 10% of Covid cases, according to the CDC. Late Thursday, both companies said their newest Covid booster shots showed promise in laboratory testing against the leading variant, dubbed « eris » or EG.5. Moderna also said its booster generated antibodies capable of taking on the « fornax » variant, or FL 1.5.1. Shares of Moderna (MRNA) and Pfizer (PFE) stock yo-yoed Friday — following their late Thursday gains on an upswing related to their updated Covid shots. In this article, we will discuss the 10 best vaccine stocks to buy now.

Despite Novavax’s surge on the stock market over the past month, the company’s shares are down by nearly 90% in the past three years. As of this writing, the biotech’s market capitalization is just under $1 billion. Perhaps some investors think that if Novavax can continue to generate the kinds of sales it did in 2022, its stock is currently undervalued and could continue to rise. The Centers for Disease Control and Prevention cleared single-strain shots from Pfizer and Moderna for all Americans six months and up on Tuesday, following approvals from the Food and Drug Administration on Monday.

FDA and CDC say yes to updated COVID boosters. Here’s what to know about the new vaccine shots for fall 2023.

Pfizer and Moderna have predicted the virus will follow that of the flu, peaking seasonally — and spurring people to go for annual vaccinations. And the companies’ investments in their coronavirus programs show they believe this is a market that could generate revenue growth over the long term. Wall Street analysts are more optimistic about Novavax’s prospects than any of the other leading vaccine makers.

And Vir is actively pursuing vaccines for hepatitis B, the flu, and HIV. With almost $1 billion in cash on the books and very promising science underpinning its pipeline, Vir looks likely to be a winner over the next several years. A company named Alnylam (ALNY 3.89%) had a pipeline bursting with RNAi therapies. While these drugs are also focused on RNA, instead of trying to create new messages (as the mRNA drugs from Moderna and BioNTech do), Alnylam’s treatments seek to inhibit certain RNA molecules.

CanSinoBIO’s inhaled COVID booster stronger against BA.1 Omicron subvariant than Sinovac shot

In a late-stage, direct-comparison study, NanoFlu proved more effective than the leading flu vaccine, Fluzone Quadrivalent. AstraZeneca’s coronavirus vaccine still isn’t available in the U.S., though. The company secured regulatory approval for its vaccine in Europe, but the relationship between AstraZeneca and the European Union has been a rocky one.

Only after these results are available will the company be able to file for emergency approval and roll out its vaccine. While this may not be a big deal considering that there’s enough room for multiple Covid vaccines, Novavax might miss out on relatively more lucrative orders from developed markets. For instance, the U.S. is now expected to increase its order for Pfizer’s vaccine to another 100 million doses. Moreover, there’s a possibility the Covid-19 vaccinations will be an ongoing process, requiring periodic booster shots, likely with new formulations, to protect against new variants of the virus and potentially diminishing immunity. Both Pfizer and Moderna are working on developing booster doses of their respective vaccines and this could mean that vaccine makers will see recurring revenues from what initially appeared like a one-off vaccine product. The U.K., for instance, has ordered an additional 60 million doses of Pfizer’s Covid vaccine for booster shots in the Fall.

And from a business standpoint, the extra cash from the vaccine is now affording Pfizer the ability to go shopping to revamp its drug pipeline and reduce the impact of a future patent cliff. Even though the industry outlook for dr and cr meaning in accounting the vaccine makers is mostly positive, there is some reason to be cautious about careless investments. One of the potential disruptors to the growth of the pharmaceutical companies is the availability of the raw material.

Best Vaccine Stocks To Buy Now

But it’s unclear how well the new shots will protect against a new omicron strain of the virus called BA.2.86, which has been identified in very small numbers in the U.S., U.K., Denmark and Israel. Vaccine nationalism is a pressing issue that needs to be addressed before firms outside the United States are hurt by the impact of these export restrictions. Already, India has overtaken Brazil as the second-most COVID-affected country in the world, surpassing 14 million infections and more than 181,000 deaths. Vaccine raw material shortages could spell disaster for the nation and the firms producing it. The shifting priorities due to COVID-19 are also affecting investors as they seek to zero in on the financial implications of the pandemic.

This Biotech Stock Offers Innovative Growth at a Massive Discount – Nasdaq

This Biotech Stock Offers Innovative Growth at a Massive Discount.

Posted: Fri, 08 Sep 2023 18:57:00 GMT [source]

With all the focus on NVX-CoV2373, though, some investors have seemingly forgotten about Novavax’s recombinant quadrivalent seasonal influenza vaccine candidate, dubbed NanoFlu. That’s unfortunate, because NanoFlu could prove to be a blockbuster in its own right, and it arguably has a better shot at delivering sustainable revenue growth than NVX-CoV2373 over the next five years. Pfizer, as market leader with 65% share right now, forecasts revenue of $13.5 billion for its coronavirus vaccine this year. The pharma giant also is a leader in the coronavirus treatment market and expects its product — Paxlovid — to bring in $8 billion this year.

The U.S. FDA is reviewing results of a study of adults who received booster doses of different vaccines than their original shots. The novel coronavirus continues to spread throughout the world and vaccine developers are responding with unprecedented speed. The genome sequence of the COVID-19 virus was released in January and the first human trials of Moderna’s vaccine candidate have already begun. The typical timeline for vaccine development can take five to seven years before approval. However, vaccine developers have been able to take advantage of previous research on coronaviruses such as SARS and MERS and are hopeful that a new vaccine could be available within 18 months. Covid vaccine makers’ shares rose Monday as new variants of the virus emerge in the U.S. ahead of the rollout of updated shots this fall.

But the emergence of BA.2.86 could potentially increase demand for vaccines and treatments that will likely provide some degree of protection against the highly mutated variant. Shares of BioNTech, which jointly develops Covid vaccines with Pfizer, closed more than 6% higher. John Moore, a professor of microbiology and immunology at Weill Cornell Medical College, told KFF Health News that he saw the new shots as « not remotely a game changer. » For Medicare, seniors will continue to pay nothing for their COVID-19 vaccinations from any providers that accept Medicare assignment, a Centers for Medicare and Medicaid Services spokesperson said. Medicare Advantage beneficiaries also will also not have to pay anything, as long as they get their shots from an in-network provider.

Shares of Moderna are down 78% from their September 2021 high of $456, making the Massachusetts-based pharmaceutical company the worst-performing stock listed on the S&P 500 during the period, according to FactSet data. BioNTech, which isn’t listed on the S&P, is also down 78% from its 2021 peak share price. Moderna and Pfizer are among the worst-performing stocks listed on the S&P this year as the rival firms both grappled with declining demand for Covid prevention and treatment. Wall Street isn’t super bullish about Johnson & Johnson (JNJ 0.25%), but at least analysts expect the big healthcare stock will rise over the next year.

Not all experts agree on whether everyone should be recommended to get the new shots, or just those at higher risk of severe disease. Anyone who just recently got one of the earlier formulations of boosters is recommended to wait two months before getting the new one. People who were recently infected have the option to wait for three months to get the shot, officials said, but can get it sooner similar to what has been previously recommended. The first shots are expected to be available at these sites by the end of the week, officials said. Shots from Pfizer and Moderna are now shipping out this week following the FDA’s authorizations and approvals for the revised mRNA vaccines.

Ocugen and Vaxart aren’t currently among the top tier of COVID-19 vaccine makers, but these biotech stocks could experience the greatest price appreciation if their experimental vaccines win regulatory approvals. Their fortunes are likely to significantly improve if the vaccines provide effective protection against emerging coronavirus variants. Although the Pfizer vaccine has been a tremendous commercial success, the pharmaceutical company’s stock hasn’t soared nearly as much as the shares of smaller vaccine makers. Pfizer’s size makes it difficult for any single product to substantially change its stock price. The company has also faced headwinds with clinical setbacks for other products. Pfizer will also lose key patents for several drugs later in the decade.

  • “In the first half of 2023, we had already generated $2 billion in sales, and that puts the second half at a $4 to $6 billion revenue range for us,” Mock explains.
  • “The way we think about it is that mRNA is the information molecule of life,” Mock explains.
  • He joined Moderna as CFO in September 2022, coming from PerkinElmer, a life sciences and diagnostics company, where he was also a finance chief.
  • After dropping steadily through the autumn, it began rising again in late November.
  • « Significant buying opportunity, » « buy while it’s cheap, » and « dead cat bounce » were some of the terms Seeking Alpha analysts used to describe their stocks, none of which are Buy-rated, according to SA’s Quant ratings.

The new COVID-19 shots come as health authorities have been gearing up for a campaign to promote other new vaccines now available for RSV, or respiratory syncytial virus, in addition to the annual seasonal influenza vaccine. The company has made moves to improve things, including efforts to reduce expenses and costs. In the first six months of the year, Novavax’s revenue of $505.4 million declined by about 43% year over year. Novavax did improve on the bottom line, with a loss per share of $2.69 through June 30, compared to the net loss per share of $3.97 reported in the comparable period of the previous fiscal year. It ended the second quarter with $518 million in cash, equivalents, and restricted cash, less than half what it had as of the end of 2022. Many of those biotechs on the front lines of the fight against the coronavirus seem to be coming back to life after their shares got hammered over the past year or more.

More News

Novavax reported a triple-digit percentage gain, though still trimmed its full-year outlook by $100 million. According to the last available data in May, just 17% of the total U.S. population had received an updated booster shot. Right now, Vir Biotechnology has three antibody therapies for COVID-19, including one that’s already been authorized by the FDA.

covid vaccine stocks

You should also consider a company’s other products and pipeline drug candidates. The stocks of drugmakers with other successful products are less risky than companies that don’t have other products on the market. While global demand is high right now for COVID-19 vaccines, questions remain about how often boosters will be needed (if at all) once the pandemic is over. TD Cowen analyst Tyler Van Buren said Wednesday’s news was unlikely to raise the share price because people already assume the mRNA vaccines will continue to be effective against new COVID variants as they crop up. Both the Moderna and Pfizer/BioNTech shots are based on mRNA technology.

The $129 dose will be free to all consumers in the U.S. and most other countries, via either insurance or access through government programs. “In the first half of 2023, we had already generated $2 billion in sales, and that puts the second half at a $4 to $6 billion revenue range for us,” Mock explains. And $2 billion was already committed with global contracts, he says. So that leaves you with a range of $2 to $4 billion, mostly in the United States, for the rest of the year,” Mock says.

If it shows promise, the concept might be applicable to other cancers too. After helping curb one of the most fatal pandemics in the last century, it would be hard to imagine a better encore than revolutionizing cancer therapy. Furthest along in the development process is its cytomegalovirus (CMV) vaccine, which is currently in phase 3 studies. Pregnant women who get infected with CMV can pass the virus on to their fetuses. Each year, about 25,000 babies in the U.S. are born infected with it, and about 20% of those have birth defects including learning disabilities, hearing loss, vision impairment, and decreased muscle strength and coordination.

Partager cet article :

Les dernières actualités de l'association


Metéo sur ensisheim

Bonne fête aux :

La fête du jour sur votre site avec